DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT05854979

Completed

Effects of GLP-1 Agonists on Gastric Volume

Ultrasound Assessment of Preoperative Gastric Volume in Fasted, Diabetic Surgical Patients: A Prospective Observational Cohort Study on the Effects of GLP-1 Agonists on Gastric Emptying

Asset

GLP-1 / incretin class catch-all

Listed sites

1

Recruiting sites

—

Enrollment

210

actual

Study population

Diabetes (other / unspecified), Perioperative / gastric aspiration risk

Key I/E criterion

•HbA1c ≥6.5%

Primary endpoint

•Gastric Volume in RLD Position

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05854979
Org study IDPro00128783

Timeline

Milestones

Study first posted2023-05-11actual
Study start2023-08-09actual
Primary completion2024-04-15actual
Study completion2024-04-15actual
Last update posted2024-04-25actual

Assets

Investigational agents

GLP-1 / incretin class catch-all

Study populations

Who this study enrolls

Diabetes (other / unspecified)Perioperative / gastric aspiration risk

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

This study will consist of patients with a diagnosis of diabetes who are or are not taking a GLP-1 medication, have appropriately fasted, and scheduled for an elective surgery with general anesthesia.

Inclusion criteria

•Age greater than or equal to 18 years old
•Diagnosed with diabetes (listed on medical record, Hgb A1C greater than or equal to 6.5%, fasting blood glucose greater than or equal to 126mg/dL, and/or on medical treatment for diabetes)
•One of the following groups:
•Taking a GLP-1 Medication
•Not taking a GLP-1 Medication
•ASA Physical Classification Status 1-3
•Scheduled for elective surgery under general anesthesia
•Appropriately fasted per ASA Fasting Guidelines 201712

Exclusion criteria

•BMI greater than 40
•Previous gastric/esophageal surgery
•Abnormal gastric anatomy
•Pregnancy
•Inability or unwillingness of subject to give informed consent
•Non-English Speaking

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes
3
Safety / tolerability / PK
1

Safety / tolerability / PK

1 endpoint
Secondary/protocol endpoint

Incidence of aspiration

Time frame:From the time surgery begins until the end of scheduled surgery, assessed up to 24 hours

event count, event

Other clinical outcomes

3 endpoints
Primary/protocol endpoint

Gastric Volume in RLD Position

Time frame:From time of enrollment until the start of surgery, assessed up to 4 weeks

descriptive

Secondary/protocol endpoint

Gastric antrum CSA in RLD position

Time frame:From time of enrollment until the start of surgery, assessed up to 4 weeks

descriptive

Secondary/protocol endpoint

Perlas antral grade

Time frame:From time of enrollment until the start of surgery, assessed up to 4 weeks

categorical status, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.